Alopecia is an undesirable side effect of cancer chemotherapy. The mitigation of alopecia is a desirable adjunct treatment for patients with cancer. FDA-cleared scalp cooling (SC) devices have been successfully used to prevent or reduce chemotherapy-induced alopecia (CIA). This paper provides an understanding of the implementation and value of the new Insurance-Based Billing Model used in the USA for SC and its benefits compared with the original self-pay model. This improved compensation change will result in all patients in need, including underserved and disadvantaged populations, receiving equitable healthcare by allowing access to this valuable supportive care technology.
Keyphrases
- chemotherapy induced
- healthcare
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- affordable care act
- quality improvement
- primary care
- health insurance
- palliative care
- prognostic factors
- climate change
- papillary thyroid
- pain management
- combination therapy
- squamous cell
- patient reported outcomes
- chronic pain
- patient reported
- replacement therapy
- smoking cessation